Cargando…

Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells

Chronic liver injury may result in hepatic fibrosis, which can progress to cirrhosis and eventually liver failure. There are no drugs that are specifically approved for treating hepatic fibrosis. The natural product honokiol (HNK), a bioactive compound extracted from Magnolia grandiflora, represents...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kataoka, Seita, Umemura, Atsushi, Okuda, Keiichiro, Taketani, Hiroyoshi, Seko, Yuya, Nishikawa, Taichiro, Yamaguchi, Kanji, Moriguchi, Michihisa, Kanbara, Yoshihiro, Arbiser, Jack L., Shima, Toshihide, Okanoue, Takeshi, Itoh, Yoshito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705910/ https://www.ncbi.nlm.nih.gov/pubmed/34948151 http://dx.doi.org/10.3390/ijms222413354

Ejemplares similares

Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis
por: Okuda, Keiichiro, et al.
Publicado: (2021)

Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress
por: Okuda, Keiichiro, et al.
Publicado: (2021)

Potential Therapeutic Targets and Promising Agents for Combating NAFLD
por: Umemura, Atsushi, et al.
Publicado: (2022)

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
por: Yano, Kota, et al.
Publicado: (2020)

FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease
por: Seko, Yuya, et al.
Publicado: (2019)

The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals
por: Seko, Yuya, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells
por: Takahashi, Aya, et al.
Publicado: (2021)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko, Yuya, et al.
Publicado: (2018)

Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice
por: Taketani, Hiroyoshi, et al.
Publicado: (2019)

Loss of KAP3 decreases intercellular adhesion and impairs intracellular transport of laminin in signet ring cell carcinoma of the stomach
por: Soda, Tomohiro, et al.
Publicado: (2022)

The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan
por: Seko, Yuya, et al.
Publicado: (2020)

The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease
por: Seko, Yuya, et al.
Publicado: (2021)

Comparison of portal vein hemodynamics with ultrasound-based elastography for the prediction of liver fibrosis in patients with chronic liver disease
por: Yamaguchi, Kanji, et al.
Publicado: (2023)

The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease
por: Seko, Yuya, et al.
Publicado: (2022)

PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
por: Okishio, Shinya, et al.
Publicado: (2020)

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions
por: Fujii, Hideki, et al.
Publicado: (2017)

Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
por: Takahashi, Aya, et al.
Publicado: (2020)

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo
por: Bonner, Michael Y., et al.
Publicado: (2016)

Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan
por: Sumida, Yoshio, et al.
Publicado: (2020)

Honokiol is a FOXM1 antagonist
por: Halasi, Marianna, et al.
Publicado: (2018)

Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling
por: Qin, Tao, et al.
Publicado: (2021)

Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease
por: Kimura, Takefumi, et al.
Publicado: (2021)

Anti-fibrotic effects of phenolic compounds on pancreatic stellate cells
por: Lin, Zesi, et al.
Publicado: (2015)

EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma
por: Yasui, Kohichiroh, et al.
Publicado: (2015)

A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus
por: Moriguchi, Michihisa, et al.
Publicado: (2017)

Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan
por: Sakakida, Tomoki, et al.
Publicado: (2023)

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies
por: Mędra, Aleksandra, et al.
Publicado: (2016)

Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3
por: Pillai, Vinodkumar B., et al.
Publicado: (2015)

Honokiol Inhibits SARS-CoV-2 Replication in Cell Culture at a Post-Entry Step
por: Salgado-Benvindo, Clarisse, et al.
Publicado: (2023)

Honokiol Alleviates Hypertrophic Scar by Targeting Transforming Growth Factor-β/Smad2/3 Signaling Pathway
por: Zhao, Danyang, et al.
Publicado: (2017)

PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells
por: Rady, Brian, et al.
Publicado: (2021)

Anti-fibrotic effects of branched-chain amino acids on hepatic stellate cells
por: Lee, Hae Lim, et al.
Publicado: (2022)

Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer
por: Avtanski, Dimiter B., et al.
Publicado: (2015)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis
por: Nagalingam, Arumugam, et al.
Publicado: (2012)

Induction of STK11-dependent cytoprotective autophagy in breast cancer cells upon honokiol treatment
por: Muniraj, Nethaji, et al.
Publicado: (2020)

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice
por: Pillai, Vinodkumar B., et al.
Publicado: (2017)

Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis
por: Nagalingam, Arumugam, et al.
Publicado: (2017)

Data on the effect of pro-fibrotic cytokine TGF-β on hepatic stellate cell autophagy
por: Thomes, Paul G., et al.
Publicado: (2016)

Antineoplastic Effects of Honokiol on Melanoma
por: Guillermo-Lagae, Ruth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p5ihiv4u97kprmqvhpce9fnsih